GBA Presents: House of Gummy-!

vanzandt · Jun 9, 2023

From the stocks that are never mentioned anywhere dept:

KNF---> $43.26

Aggregates Stoney!
Rocks and asphalt.<------

---------------------------------------

Knife River Corporation Completes Spinoff from MDU Resources

Knife River Corporation (NYSE: KNF) today announced the successful completion of its spinoff from MDU Resources Group, Inc. (NYSE: MDU). As a result of the spinoff, Knife River is now an independent, public company that will begin “regular way” trading this morning on the New York Stock Exchange.

“The opportunity to ring the opening bell at the New York Stock Exchange this morning, representing nearly 6,000 dedicated Knife River team members, is truly an honor and is an exciting moment in our company’s history,” said Brian R. Gray, president and CEO of Knife River. “Our team is well-established and well prepared to be on our own as a pure-play construction materials and contracting services company. We are focused on building America’s infrastructure and delivering long-term value for our shareholders.”

__________________________

Knife River Corporation, a member of the S&P MidCap 400 index, mines aggregates and markets crushed stone, sand, gravel and related construction materials, including ready-mix concrete, asphalt and other value-added products. It also distributes cement and asphalt oil. It performs integrated contracting services. For more information about Knife River, visit www.kniferiver.com.

------------------------------------------------

NEW YORK, May 25, 2023 /PRNewswire/ -- Knife River Corp. (NYSE: KNF) will be added to the S&P MidCap 400 prior to the open of trading on Thursday, June 1 following its spin-off from S&P MidCap 400 constituent MDU Resources Group Inc. (NYSE: MDU). Effective prior to the open of trading on Friday, June 2, S&P MidCap 400 constituent Bank of Hawaii Corp. (NYSE:BOH) will replace HomeStreet Inc. (NASD:HMST) in the S&P SmallCap 600. Post spin-off, parent company MDU Resources Group will remain in the S&P MidCap 400. Bank of Hawaii and HomeStreet are no longer representative of the mid and small-cap market spaces, respectively.

_____________________________________

Edit: $35 (6/1) to $43 may be too far too fast. Lets put it on a watchlist.

vanzandt · Jun 9, 2023

vanzandt said:
I was just gonna say... I DID IT AGAIN...
VZ calls the perfect bottom on DAL at $31

If you listened to me Stoney, your tax bill would put a dent in the budget deficit.

You should have listened Stoney!
How many times have I told you, there's more to stocks than their current price.

vanzandt said:
Best CEO out there.
If Bastion ever jumps ship to another company... follow him and bet the farm.

stonedinvestor · Jun 9, 2023

Why Shares of Outlook Therapeutics Rose Tuesday

Key Points

Outlook, a clinical-stage biotech, is awaiting potential approval for a wet AMD therapy.

The therapy has a PDUFA date of Aug. 29 from the FDA.

Outlook will receive logistics and distribution help from AmerisourceBergen to market the therapy.

NASDAQ: OTLK
Outlook Therapeutics

Market Cap
$447M

Today's Change
(-1.44%) -$0.03
Current Price
$1.72
Price as of June 9, 2023, 1:06 p.m. ET

Shares of Outlook Therapeutics (OTLK -1.44%) were up 6.3% early Tuesday afternoon after rising as much as 16% earlier in the day. The stock went past $2 a share, reaching a 52-week high in the morning at $2.03 before falling back. It was the second consecutive day the healthcare stock reached a 52-week high, as it climbed to $1.895 on Monday.

NASDAQ: OTLK
Outlook Therapeutics
Today's Change
(-1.44%) -$0.03
Current Price
$1.72

So what
The clinical-stage biotech is awaiting a key prescription drug user fee action date (PDUFA) on Aug. 29 for ONS-5010 (bevacizumab) to treat wet age-related macular degeneration (AMD). The drug is already being used extensively off label by compounding pharmacies to treat wet AMD.

With the anticipation of an approval from the Food and Drug Administration (FDA), investors have been piling in on the stock. It didn't hurt that the company also reported smaller-than-expected losses in the second quarter last month.

If approved, ONS-5010 will end the need to use unapproved repackaged IV bevacizumab from compounding pharmacies to treat wet AMD. Outlook says it plans to sell ONS-5010 in vial and prefilled syringe formulations.

Now what
The target market for ONS-5010 is potentially large, as wet AMD is the leading cause of vision loss for those 50 and older, according to Johns Hopkins Medicine. In wet AMD, abnormal blood vessels grow beneath the retina and often leak fluid and blood, creating a large blind spot in the center of the eye.

Retinal diseases, including wet AMD, diabetic retinopathy, diabetic macular edema, and retinal vein occlusion, impact 34.5 million patients in the U.S., Great Britain, Europe, China, Japan, and Australia, according to Outlook, and it is possible ONS-5010 could have wider applications beyond wet AMD.

Last September, the company entered into a partnership with AmerisourceBergen to help with marketing and distributing ONS-5010 in the U.S. With only $43.7 million in cash as of the second quarter, Outlook will need to raise funds to help ramp up the launch of the drug.

stonedinvestor · Jun 9, 2023

We jumped out of OTLK I can't remember why.

Prob should watch list this.

stonedinvestor · Jun 9, 2023

vanzandt said:
AI-Controlled Drone Goes Rogue, Kills Human Operator in USAF Simulated Test
An AI-enabled drone killed its human operator in a simulated test conducted by the U.S. Air Force in order to override a possible "no" order stopping it from completing its mission, the USAF's Chief of AI Test and Operations revealed at a recent conference.